 |
National Tax Service. (photo = National Tax Service) |
[Alpha Biz= Reporter Kim Jisun] The National Tax Service (NTS) has launched a special tax audit on Hanmi Pharmaceutical Group, which is currently involved in a management dispute.
According to industry sources on the 26th, the NTS's Central Regional Office dispatched investigators to Hanmi Pharmaceutical’s headquarters in Songpa-gu, Seoul, the previous day to seize documents necessary for the audit.
This investigation is reportedly focused on probing allegations of unfair internal transactions between Loonmeikang, a subsidiary of Kore Group owned by Hanmi Science’s Executive Director Lim Jong-yoon, and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical. Hanmi Science is the holding company of Hanmi Pharmaceutical Group.
Loonmeikang has been distributing and selling Beijing Hanmi’s pharmaceuticals in China, raising suspicions of unfair preferential transactions and price manipulation. In response, Hanmi Pharmaceutical conducted an internal investigation into these allegations through its audit committee in July. Transactions between Hanmi Pharmaceutical and Loonmeikang last year amounted to approximately 214.2 billion KRW.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
